The stock price of Bioventus (BVS) has more than doubled in the past six months. This upside can be attributed to the encouraging sales performance across its business segments, based on which management raised the 2024 guidance twice this year.In the past six months, BVS stock significantly outperformed the industry’s 5.1% rise. The stock has also outperformed the sector and the S&P 500 during the same period. BVS shares are also trading above the 50-day and 200-day moving averages.BVS Stock Outperforms In ...